Le cluster Antibodies, Monoclonal (therapeutic use) - Yttrium Radioisotopes (therapeutic use)
| 000038 (2007) | Erin Cooney-Qualter (États-Unis) ; Mark Krailo ; Anne Angiolillo ; Rashid A Fawwaz ; Gregory Wiseman ; Lauren Harrison ; Virginia Kohl ; Peter C Adamson ; Janet Ayello ; Carmella vande Ven ; Sherrie L Perkins ; Mitchell S Cairo ; | A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. |
| 000041 (2005) | Peter S Conti (États-Unis) ; Christine White ; Peter Pieslor ; Arturo Molina ; Jacqueline Aussie ; Paul Foster | The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. |
| 000049 (2002) | Thierry Alcindor (États-Unis) ; Thomas E Witzig | Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. |
| 000046 (2004) | Rodney J Ellis (États-Unis) ; Edward Kim ; Ryan Foor | Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma. |
| 000052 (2002) | Lester M Crawford | From the Food and Drug Administration. |
| This area was generated with Dilib version V0.5.76. |  |